Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dantrolene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 12/20 | 1.00 |
| ▸ | MEN1 | O00255 | 7/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 7/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 1.00 |
| ▸ | CISD1 | Q9NZ45 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.67 |
| ▸ | TP53 | P04637 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | MAOA | P21397 | 1/20 | 0.67 |
| ▸ | CASP7 | P55210 | 1/20 | 0.67 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.67 |
| ▸ | BLM | P54132 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dantrolene SCHEMBL40893 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ALMNATDP1 | |
| Dantrolene SCHEMBL946529 | 0.99 | MAPT (0.98) | MAPTMEN1KMT2ALMNATDP1 | |
| Dantrolene SCHEMBL29510578 | 0.99 | MAPT (0.98) | MAPTMEN1KMT2ALMNATDP1 | |
| Dantrolene SCHEMBL2903716 | 0.99 | MAPT (0.98) | MAPTMEN1KMT2ALMNATDP1 | |
| Dantrolene SCHEMBL2903719 | 0.99 | MAPT (0.98) | MAPTMEN1KMT2ALMNATDP1 | |
| Dantrolene SCHEMBL4223149 | 0.99 | MAPT (0.98) | MAPTMEN1KMT2ALMNATDP1 | |
| Dantrolene SCHEMBL979318 | 0.99 | MAPT (0.98) | MAPTMEN1KMT2ALMNATDP1 | |
| Dantrolene SCHEMBL1074050 | 0.98 | MAPT (0.96) | MAPTMEN1KMT2ALMNATDP1 | |
| Dantrolene SCHEMBL1074048 | 0.98 | MAPT (0.96) | MAPTMEN1KMT2ALMNATDP1 | |
| Dantrolene SCHEMBL1074051 | 0.98 | MAPT (0.96) | MAPTMEN1KMT2ALMNATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 8588 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4741492-A2 | NECROSIS INHIBITOR | Linkgevity Limited (GB) | 2026-05-13 | — | — | EP | claimed |
| US-12605364-B2 | Methods of treating SARS-CoV-2 infections | EAGLE PHARMACEUTICALS, INC. (US) | 2026-04-21 | — | — | US | claimed |
| EP-4725506-A2 | THE PEPTIDOMIMETIC COMPOUND (R)-2-AMINO-N-((S)-L-(((S)-5-AMINO-L-(3-BENZYL-1,2,4-OXADIAZOL-5-YL)PENTYL)AMINO)-3-(4-HYDROXY-2,6-DIMETHYLPHENYL)-1-OXOPROPAN-2-YL)-5-GUANIDINOPENTANAMIDE FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | Stealth BioTherapeutics Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| US-12594388-B2 | Device to deliver a predetermined amount of a substance to a natural orifice of the body | APTARGROUP, INC. (US) | 2026-04-07 | — | — | US | claimed |
| US-12588828-B2 | Methods and systems for diagnosing and treating fibromyalgia | KATZ ROBERT S (US) | 2026-03-31 | — | — | US | claimed |
| US-12582633-B2 | Methods of treating severe acute respiratory syndrome | EAGLE PHARMACEUTICALS, INC. (US) | 2026-03-24 | — | — | US | claimed |
| US-20260053804-A1 | Compositions and Methods for the Restoration of Ciliary Function | UNIV YALE (US) | 2026-02-26 | — | — | US | claimed |
| EP-3986401-B1 | THE PEPTIDOMIMETIC COMPOUND (R)-2-AMINO-N-((S)-L-(((S)-5-AMINO-L-(3-BENZYL-1,2,4-OXADIAZOL-5-YL)PENTYL)AMINO)-3-(4-HYDROXY-2,6-DIMETHYLPHENYL)-1-OXOPROPAN-2-YL)-5-GUANIDINOPENTANAMIDE FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | STEALTH BIOTHERAPEUTICS INC (US) | 2026-01-28 | — | — | EP | claimed |
| EP-4648769-A2 | NECROSIS INHIBITOR | Linkgevity Limited (GB) | 2025-11-19 | — | — | EP | claimed |
| US-20250319055-A1 | COMPOSITIONS FOR TREATING GENITAL HERPES AND METHODS OF THEIR USE | PAGARI LIFE SCIENCE CORP (US) | 2025-10-16 | — | — | US | claimed |
| WO-1999055314-A1 | FIBRINOGEN COATED DROPLETS OF LIQUID HYDROPHOBIC PHASES | UNIVERSITY OF CINCINNATI (US) | 1999-11-04 | — | — | WO | claimed |
| US-5770221-A | HIGH AND LOW MOLECULAR WEIGHT POLYISOBUTYLENE | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 1998-06-23 | — | — | US | claimed |
| CN-1171937-A | Methods of inducing analgesia or anesthesia and treating or preventing ischemic injury of tissues in general | MEDDISS INC (JP) | 1998-02-04 | — | — | CN | claimed |
| EP-0580860-B1 | METHOD OF MANUFACTURING SOLID DISPERSION | NIPPON SHINYAKU CO LTD (JP) | 1997-10-22 | — | — | EP | claimed |
| EP-0797992-A2 | Use of taurine, homotaurine and/or methionine for inducing analgesia or anesthesia and treating or preventing ischaemic injury | Meddiss, Inc. (JP) | 1997-10-01 | — | — | EP | claimed |
| US-5560933-A | INCLUDES BIOCOMPATIBLE POLYMER CAPABLE OF BEING CROSSLINKED BY DISULFIDE BONDS TO PRODUCE SHELL | VIVORX PHARMACEUTICALS, INC. (US) | 1996-10-01 | — | — | US | claimed |
| US-5439686-A | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor | VIVORX PHARMACEUTICALS, INC. (US) | 1995-08-08 | — | — | US | claimed |
| WO-1994003166-A1 | IBUPROFEN-MUSCLE RELAXANT COMBINATIONS | MERCK & CO., INC. (US) | 1994-02-17 | — | — | WO | claimed |
| EP-0205492-A1 | ANALGESIC, ANTI-INFLAMMATORY AND SKELETAL MUSCLE RELAXANT COMPOSITIONS | SUNSHINE, Abraham (US) | 1986-12-30 | — | — | EP | claimed |
| WO-1986003681-A1 | ANALGESIC, ANTI-INFLAMMATORY AND SKELETAL MUSCLE RELAXANT COMPOSITIONS | SUNSHINE ABRAHAM | 1986-07-03 | — | — | WO | claimed |